Page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 Page 10 Page 11 Page 12 Page 13 Page 14 Page 15 Page 16 Page 17 Page 18 Page 19 Page 20 Page 21 Page 22 Page 23 Page 24 Page 25 Page 26 Page 27 Page 28 Page 29 Page 30 Page 31 Page 327 DEVICE TAX REPEAL 2016 began auspiciously with implementation in January of a two-year suspension of the innovation-crushing medical device tax, marking a key turning point in AdvaMed’s seven-year campaign to repeal this onerous tax. During the year, AdvaMed redoubled its advocacy on Capitol Hill to keep the urgent need for full and permanent repeal of the tax front-of-mind for policymakers. Fundamental to this effort was educating lawmakers on how the nearly $2 billion in annual tax savings from the suspension was being redeployed by the medtech industry to develop the next-generation of treatments and cures for patients, and to create more good-paying American jobs. AdvaMed organized the industry behind a united message emphasizing the benefits of suspension and the need for permanent repeal to bolster future investments and economic growth. This included collecting broad survey data on the positive impact of suspension, as well as organizing dozens of individual examples of how specific companies were reinvesting. This message was carried through multiple Capitol Hill “fly-ins” with company CEOs and R&D executives, as well as a public affairs campaign inside the beltway and in key states, and echoed by our allies and partners in the patient and research group communities. In the fourth quarter of the year, AdvaMed augmented this work with an even more pointed message to Congress on the need for full repeal, to position the issue for action in 2017. As a result, repeal of the device tax featured prominently in Republican blue prints for health care reform and tax reform in the 115th Congress. Utah Senator Orrin Hatch was honored for his strong support of medical device tax repeal during an August tour of a C.R. Bard facility in Salt Lake City, accompanied by Chairman and CEO Timothy Ring and AdvaMed’s Scott Whitaker (at right). Minnesota Senator Amy Klobuchar (at left) and Indiana Senator Dan Coats (at right) discuss device tax repeal and other priorities with members of AdvaMed’s State Medical Technology Alliance in March. Minnesota Congressman Erik Paulsen (at left) discusses device tax repeal strategy with AdvaMed’s JC Scott on the sidelines of AdvaMed 2016 in October.